News &amp; Updates

Visual acuity (VA) of eyes initially treated with antivascular endothelial growth factor (anti-VEGF) therapy has improved from baseline to 5 years without protocol-defined treatment after follow-up ended at 2 years, a study has found. Additionally, mean retinal thickness is comparable at 2 and 5 years, but mean VA has worsened during this period.

Anti-VEGF therapy improves 5-year VA of eyes in diabetic macular oedema

Atezolizumab-bevacizumab may change the treatment landscape of liver cancer

04 Sep 2020 by

Safety data from the phase III IMbrave150 trial reinforce the previously reported favourable safety profile of atezolizumab-bevacizumab compared with sorafenib for unresectable hepatocellular carcinoma (HCC).

Atezolizumab-bevacizumab may change the treatment landscape of liver cancer

Nivolumab-ipilimumab combo may benefit Asian patients with advanced HCC

04 Sep 2020 by

A subgroup analysis of Asian patients enrolled in the CheckMate 040* trial presented at ESMO GI 2020 showed that the nivolumab + ipilimumab (NIVO + IPI) combination regimen had an efficacy and safety profile that was similar to that of the overall population.

Nivolumab-ipilimumab combo may benefit Asian patients with advanced HCC

CheckMate 459: Greater OS with nivolumab over sorafenib in advanced HCC

In patients with advanced hepatocellular carcinoma (HCC), first-line treatment with nivolumab may confer greater overall survival (OS) than sorafenib, according to updated results of the phase III CheckMate 459* study.

CheckMate 459: Greater OS with nivolumab over sorafenib in advanced HCC

Hepatitis B cure: Several investigational drugs shoot at victory

Hope for a hepatitis B virus cure becomes manifest as multiple drugs from recent clinical trials show potential in transforming the battle against the disease.

Hepatitis B cure: Several investigational drugs shoot at victory

Obesity not associated with febrile neutropaenia during levofloxacin prophylaxis

Obesity is not a good reason to initiate more aggressive levofloxacin dosing schemes when used for febrile neutropaenia prophylaxis in patients with haematological malignancies receiving intermediate-risk myelosuppressive chemotherapy, suggests a study.

Obesity not associated with febrile neutropaenia during levofloxacin prophylaxis

Regorafenib improves survival in advanced HCC patients progressing on sorafenib

Real-world systemic sequential therapy with regorafenib confers survival benefits in patients with advanced hepatocellular carcinoma (HCC) who failed first-line sorafenib, consistent with previous clinical trial, according to a study in Korea.

Regorafenib improves survival in advanced HCC patients progressing on sorafenib

Sorafenib plus hepatic arterial infusion chemo safe, effective in advanced HCC

Treatment with sorafenib plus hepatic arterial infusion chemotherapy (SoraHAIC) for advanced hepatocellular carcinoma (HCC) has been shown to be safe and effective in a recent study.

Sorafenib plus hepatic arterial infusion chemo safe, effective in advanced HCC

Nintedanib continues to show promise for progressive fibrosing ILDs

Interim analyses of the INBUILD trial presented at ATS 2020 continue to reflect the benefit of the tyrosine kinase inhibitor nintedanib for individuals with progressive fibrosing interstitial lung diseases (ILDs).

Nintedanib continues to show promise for progressive fibrosing ILDs

Systemic JIA: Tapering canakinumab feasible in children in complete remission

For paediatric patients who achieved complete remission (CR) on canakinumab, it is possible to maintain this response while reducing exposure to the drug, as shown in a study.

Systemic JIA: Tapering canakinumab feasible in children in complete remission